Chair and Presenter Neal D. Shore, MD, FACS, Sia Daneshmand, MD, and Guru P. Sonpavde, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA activity titled “Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/40qGkJH. CME/MOC/AAPA credit will be available until December 28, 2024.
Chair and Presenters Matthew D. Galsky, MD, Shilpa Gupta, MD, and Andrea Necchi, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA/IPCE activity titled “Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3QlbwW0. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.
Chair and Moderator, Petros Grivas, MD, PhD, Shilpa Gupta, MD, and Gary D. Steinberg, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC activity titled “Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2WcJp3n. CME/MOC credit will be available until December 31, 2022.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Richard S. Finn, MD, Anthony El-Khoueiry, MD, and Josep M. Llovet, MD, PhD, prepared useful practice aids pertaining to hepatocellular carcinoma for this CME activity titled "Breaking the Paradox: Expanding Options and New Questions in HCC Management: Mapping the Pathways to Better Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2HU6L5K. CME credit will be available until February 14, 2020.
Chair, Amit Singal, MD, MS, Anthony El-Khoueiry, MD, Ahmed Omar Kaseb, MD, CMQ, and Anjana Pillai, MD, prepared useful Practice Aids pertaining to hepatocellular carcinoma for this CME/MOC activity titled “It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration & Modern Therapeutics.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3AbNtC5. CME/MOC credit will be available until December 4, 2023.
Tonight’s speakers: Dr. Dan Sargent and Kim Ryan
Disclaimer: “This Report is not an official event of the 2012 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the cosponsoring organizations of the 2012 Gastrointestinal Cancers Symposium.”
Jorge A. Marrero, MD, MS, Anthony El-Khoueiry, MD, Richard S. Finn, MD, and Laura M. Kulik, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Pj9wM8. CME credit will be available until December 20, 2019.
Chair and Presenters Matthew D. Galsky, MD, Shilpa Gupta, MD, and Andrea Necchi, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/AAPA/IPCE activity titled “Making an Impact in Bladder Cancer Care: Integrating the Latest Evidence and Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3QlbwW0. CME/MOC/AAPA/IPCE credit will be available until February 26, 2025.
Chair and Moderator, Petros Grivas, MD, PhD, Shilpa Gupta, MD, and Gary D. Steinberg, MD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC activity titled “Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2WcJp3n. CME/MOC credit will be available until December 31, 2022.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Richard S. Finn, MD, Anthony El-Khoueiry, MD, and Josep M. Llovet, MD, PhD, prepared useful practice aids pertaining to hepatocellular carcinoma for this CME activity titled "Breaking the Paradox: Expanding Options and New Questions in HCC Management: Mapping the Pathways to Better Patient Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2HU6L5K. CME credit will be available until February 14, 2020.
Chair, Amit Singal, MD, MS, Anthony El-Khoueiry, MD, Ahmed Omar Kaseb, MD, CMQ, and Anjana Pillai, MD, prepared useful Practice Aids pertaining to hepatocellular carcinoma for this CME/MOC activity titled “It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration & Modern Therapeutics.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3AbNtC5. CME/MOC credit will be available until December 4, 2023.
Tonight’s speakers: Dr. Dan Sargent and Kim Ryan
Disclaimer: “This Report is not an official event of the 2012 Gastrointestinal Cancers Symposium. Not sponsored or endorsed by any of the cosponsoring organizations of the 2012 Gastrointestinal Cancers Symposium.”
Jorge A. Marrero, MD, MS, Anthony El-Khoueiry, MD, Richard S. Finn, MD, and Laura M. Kulik, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "Surveying the View From the Driver’s Seat in Hepatocellular Carcinoma: Bringing Into Focus Hepatology’s Key Role in Guiding HCC Care Down the Path to Improved Outcomes." For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2Pj9wM8. CME credit will be available until December 20, 2019.
Poster presentation at the 2016 WORLD GASTROINTESTINAL SYMPOSIUM on tepotinib a selective inhibitor of c-MET by S. Faivre, J.-F. Blanc, P. Merle, A. Fasolo, A. Iacobellis, V. Grando, T. Decaens, J. Trojan, E. Villa, U. Stammberger, R. Bruns, E. Raymond
1Oncology Unit, Beaujon University Hospital, Clichy, France; 2Service d’hépato-gastroentérologie et d’oncologie digestive, Groupe Hospitalier Saint André, Bordeaux, France; 3Service d'Hépato-Gastro-Entérologie, Hôpital de la Croix Rousse, Lyon, France; 4Dipartimento di Oncologia Medica, Ospedale San Raffaele IRCSS, Milan, Italy; 5Servizio di Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy; 6Service Hépatologie, Hôpital Jean-Verdier, Bondy, France; 7Service d'hepato-gastro-enterologie, CHU de Grenoble - Hôpital Nord, Grenoble, France; 8Gastrointestinal Oncology, Goethe University Hospital, Frankfurt, Germany; 9Policlinico di Modena, Modena, Italy; 10Merck KGaA, Darmstadt, Germany
Co-Chairs and Presenter Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC, and Patrick M. Forde, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/AAPA activity titled “A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MQVu5l. CME/MOC/CC/AAPA credit will be available until February 27, 2025.
Mgh COVID-19 Treatment Guidance March 17, 2020Ken Yale
This document was developed by members of the ID division at MGH in conjunction with pharmacy, radiology, and other medicine divisions to provide guidance to frontline clinicians caring for patients with COVID-19. This document covers potential off-label and/or experimental use of medications and immunosuppression management for transplant patients as well as a suggested laboratory work up. It does NOT cover recommendations for infection control, PPE, management of hypoxemia or other complications in patients with COVID-19. This is a living document that will be updated in real time as more data emerge.
Chair, Anthony R. Mato, MD, MSCE, Kristen Battiato, MSN, RN, AGNP-C, Dipti Gupta, MD, MPH, and Amber C. King, PharmD, BCOP, prepared useful Practice Aids pertaining to B-cell cancers for this CME/MOC/NCPD activity titled “Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at http://bit.ly/3cHX3zm. CME/MOC/NCPD credit will be available until October 3, 2023.
Chair & Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Tiffany A. Richards, PhD, ANP-BC, AOCNP, prepared useful Practice Aids pertaining to multiple myeloma for this NCPD/ILNA activity titled “Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA information, and to apply for credit, please visit us at https://bit.ly/3ZSymre. NCPD/ILNA credit will be available until May 27, 2024.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and R. Kate Kelley, MD, prepared useful Practice Aids pertaining to liver cancer for this CME/CE activity titled "Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor Board Evaluating the Potential of Immunotherapy and Novel Targeted Approaches." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2FG0J75. CME/CE credit will be available until March 25, 2019.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and Richard S. Finn, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "New Options, Emerging Combinations in Advanced Hepatocellular Carcinoma: Are Management Approaches Poised For Transformation?" For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2okTvdb. CME credit will be available until March 7, 2019.
Chair and Presenter, Brenda Martone, MSN, ANP-BC, AOCNP, Archana Ajmera, MSN, ANP-BC, AOCNP, and Tian Zhang, MD, MHS, prepared useful Practice Aids pertaining to bladder cancer for this CME/NCPD/ILNA/IPCE activity titled “Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3JpnIRU. CME/NCPD/ILNA/IPCE credit will be available until May 28, 2024.
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
More Related Content
Similar to Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care
Poster presentation at the 2016 WORLD GASTROINTESTINAL SYMPOSIUM on tepotinib a selective inhibitor of c-MET by S. Faivre, J.-F. Blanc, P. Merle, A. Fasolo, A. Iacobellis, V. Grando, T. Decaens, J. Trojan, E. Villa, U. Stammberger, R. Bruns, E. Raymond
1Oncology Unit, Beaujon University Hospital, Clichy, France; 2Service d’hépato-gastroentérologie et d’oncologie digestive, Groupe Hospitalier Saint André, Bordeaux, France; 3Service d'Hépato-Gastro-Entérologie, Hôpital de la Croix Rousse, Lyon, France; 4Dipartimento di Oncologia Medica, Ospedale San Raffaele IRCSS, Milan, Italy; 5Servizio di Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy; 6Service Hépatologie, Hôpital Jean-Verdier, Bondy, France; 7Service d'hepato-gastro-enterologie, CHU de Grenoble - Hôpital Nord, Grenoble, France; 8Gastrointestinal Oncology, Goethe University Hospital, Frankfurt, Germany; 9Policlinico di Modena, Modena, Italy; 10Merck KGaA, Darmstadt, Germany
Co-Chairs and Presenter Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC, and Patrick M. Forde, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/AAPA activity titled “A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MQVu5l. CME/MOC/CC/AAPA credit will be available until February 27, 2025.
Mgh COVID-19 Treatment Guidance March 17, 2020Ken Yale
This document was developed by members of the ID division at MGH in conjunction with pharmacy, radiology, and other medicine divisions to provide guidance to frontline clinicians caring for patients with COVID-19. This document covers potential off-label and/or experimental use of medications and immunosuppression management for transplant patients as well as a suggested laboratory work up. It does NOT cover recommendations for infection control, PPE, management of hypoxemia or other complications in patients with COVID-19. This is a living document that will be updated in real time as more data emerge.
Chair, Anthony R. Mato, MD, MSCE, Kristen Battiato, MSN, RN, AGNP-C, Dipti Gupta, MD, MPH, and Amber C. King, PharmD, BCOP, prepared useful Practice Aids pertaining to B-cell cancers for this CME/MOC/NCPD activity titled “Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at http://bit.ly/3cHX3zm. CME/MOC/NCPD credit will be available until October 3, 2023.
Chair & Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Tiffany A. Richards, PhD, ANP-BC, AOCNP, prepared useful Practice Aids pertaining to multiple myeloma for this NCPD/ILNA activity titled “Betting on BCMA in Multiple Myeloma: Oncology Nurse Principles for Delivering Effective Care With BCMA Antibodies and Cellular Therapy.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA information, and to apply for credit, please visit us at https://bit.ly/3ZSymre. NCPD/ILNA credit will be available until May 27, 2024.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and R. Kate Kelley, MD, prepared useful Practice Aids pertaining to liver cancer for this CME/CE activity titled "Teaming Up to Improve Outcomes in Advanced Hepatocellular Carcinoma: A Tumor Board Evaluating the Potential of Immunotherapy and Novel Targeted Approaches." For the full presentation, monograph, complete CME/CE information, and to apply for credit, please visit us at http://bit.ly/2FG0J75. CME/CE credit will be available until March 25, 2019.
Ghassan Abou-Alfa, MD, MBA, Anthony El-Khoueiry, MD, and Richard S. Finn, MD, prepared useful practice aids pertaining to HCC management for this CME activity titled "New Options, Emerging Combinations in Advanced Hepatocellular Carcinoma: Are Management Approaches Poised For Transformation?" For the full presentation, monograph, complete CME information, and to apply for credit, please visit us at http://bit.ly/2okTvdb. CME credit will be available until March 7, 2019.
Chair and Presenter, Brenda Martone, MSN, ANP-BC, AOCNP, Archana Ajmera, MSN, ANP-BC, AOCNP, and Tian Zhang, MD, MHS, prepared useful Practice Aids pertaining to bladder cancer for this CME/NCPD/ILNA/IPCE activity titled “Meeting Patient Needs Through Optimal Nursing Strategies in Personalized Bladder Cancer Care.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3JpnIRU. CME/NCPD/ILNA/IPCE credit will be available until May 28, 2024.
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, discuss non-cystic fibrosis bronchiectasis in this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Jonathan E. McConathy, MD, PhD, and Gil Rabinovici, MD, discuss Alzheimer's disease in this CME/AAPA activity titled “Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/45RFl6g. CME/AAPA credit will be available until June 15, 2025.
Co-Chairs Sarah Hayward, PharmD, BCOP, and Ambar Khan, PharmD, BCOP, discuss endometrial and cervical cancers in this CME/CPE/IPCE activity titled “A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care.” For the full presentation, downloadable Practice Aids, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3wGBPQp. CME/CPE/IPCE credit will be available until May 27, 2025.
Co-Chairs, Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD, discuss multiple myeloma in this CME activity titled “‘Four-Ward’ Progress in NDMM: New Developments With CD38 Antibody Quadruplets.” For the full presentation and complete CME information, and to apply for credit, please visit us at https://bit.ly/3x3oWA3. CME credit will be available until May 23, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss lung cancer in this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair Oliver Sartor, MD, discusses prostate cancer in this CME activity titled “On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/49oY4IJ. CME credit will be available until May 23, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair, Nicholas J. Short, MD, discusses acute lymphoblastic leukemia in this CME/NCPD/CPE/AAPA/IPCE activity titled “Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42QsTDT. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.
Chair, Sharon Cohen, MD, FRCPC, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair, Sharon Cohen, MD, FRCPC, discusses Alzheimer’s disease in this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair and Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Charise Gleason, MSN, NP-C, AOCNP, discuss multiple myeloma in this CME/MOC/NCPD/ILNA/IPCE activity titled “Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/47mtUnM. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, discuss NSCLC in this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs, Sia Daneshmand, MD, and Matthew D. Galsky, MD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3OOeYbO. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 13, 2025.
Chair Jamie Carroll, APRN, CNP, MSN, discusses breast cancer in this NCPD/ILNA/AAPA activity titled “Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at https://bit.ly/3SdnvWt. NCPD/ILNA/AAPA credit will be available until May 8, 2025.
Chair Jonathan A. Bernstein, MD, discusses chronic spontaneous urticaria in this CME activity titled “BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3P0cnvi. CME credit will be available until May 6, 2025.
Co-Chairs Milind Desai, MD, MBA, FACC, FAHA, FESC, and Andrew Willeford, PharmD, PhD, BCCP, prepared useful Practice Aids pertaining to hypertrophic cardiomyopathy for this CME/MOC/CPE/AAPA/IPCE activity titled “Adapting Managed Care Strategies in the Era of Precision Medicine for Hypertrophic Cardiomyopathy.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/4bb7eKc. CME/MOC/CPE/AAPA/IPCE credit will be available until May 16, 2025.
More from PVI, PeerView Institute for Medical Education (20)
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Pioneering Precision Medicine in Bladder Cancer: Multidisciplinary Perspectives on Personalizing Patient Care
1. Treatments Used in Bladder Cancer
Full abbreviations, accreditation, and disclosure information available at PeerView.com/XJV40
Counseling Patients on irAEs Associated With Immune Checkpoint Inhibitors1-4
Patient education must focus
on the importance of prompt
recognition and management
of irAEs
Grade 1
Minimal or no symptoms; diagnostic change only
• In general, immune checkpoint inhibitor therapy should be continued with
close monitoring, with the exception of some neurologic, hematologic, and
cardiac toxicities
Grade 2
Mild to moderate symptoms
• Hold checkpoint inhibitor therapy for most grade 2 toxicities
• Consider resuming immunotherapy when symptoms and/or laboratory
values revert to grade 1 or lower
• Corticosteroids (initial dose of 0.1-1 mg/kg/d of prednisone or equivalent)
may be administered
Grade 3/4
Severe or life-threatening symptoms
Grade 3
• Hold checkpoint inhibitor therapy
• Initiate high-dose corticosteroids (prednisone 1-2 mg/kg/d or
methylprednisolone IV 1-2 mg/kg/d)
• If symptoms do not improve with 48-72 h of high-dose corticosteroids,
infliximab may be offered for some toxicities
• Taper corticosteroids over the course of at least 4-6 wk
• When symptoms and/or laboratory values revert to grade 1 or lower,
rechallenging with immunotherapy may be offered; however, caution is
advised, especially in those patients with early-onset irAEs; dose
adjustments are not recommended
Grade 4
• In general, permanent discontinuation of checkpoint inhibitor therapy is
warranted, with the exception of endocrinopathies that have been
controlled by hormone replacement
irAE Grading and Management: Overall
• Diarrhea
• Nausea/Vomiting
• Hepatitis
Gastrointestinal
• Hypothyroidism
Endocrine
• Rash
• Pruritus
Dermatologic
• Pneumonitis
Pulmonary
irAEs Can Affect Any Organ System …
… And the Timing of Events Is Variable
Duration of Treatment, wk
0 4 6 8 10 12 14 >30
Toxicity,
Grade
Colitis
Endocrinopathy
Nephritis
Liver toxicity
Skin,
rash, or
pruritus
Pneumonitis
2. Treatments Used in Bladder Cancer
Full abbreviations, accreditation, and disclosure information available at PeerView.com/XJV40
Educating Patients About ADCs5-7
Enfortumab
Vedotin (EV)
Sacituzumab
Govitecan (SG)
Dosing
Schedule
2 doses in a
21-d cycle
Infusion
Time
Administered over 3 h
for the first dose,
with subsequent doses
administered over 1-2 h
Dose
Rounding
Administered
over 30 min
3 doses in a 28-d cycle
as monotherapy
2 doses in a 21-d cycle
in combination with
pembrolizumab
Available as 20-mg and
30-mg vials, allowing
flexibility with dose
rounding
Available as a
180-mg vial
Assess patients with a thorough
history and physical examination
Screen for pre-existing neuropathy
or diabetes mellitus
Before a patient starts
treatment with either
EV or SG …
• There is a risk of infusion-related reactions
• Although rare, grade 3-4 reactions do occur
– Infusion-site extravasation observed with
EV; ensure adequate venous access
prior to infusion
• Hypersensitivity reactions, ranging from mild
to anaphylaxis, have been seen within 24 h
of SG administration
– Premedicate with an antipyretic and H1
and H2 blockers prior to each infusion
– Have medication and emergency
equipment to treat such reactions ready
for immediate use
• Monitor patients during the infusion and for
≥30 min after completion of infusion
Safety Considerations With ADCs
Peripheral Neuropathy
• Generally resolves/remains at grade 1
Hyperglycemia
• Monitor blood glucose in patients with/at
risk for diabetes or hyperglycemia
Ocular Disorders
• Monitor and consider prophylactic
artificial tears for dry eyes and treatment
with ophthalmic topical steroids after an
ophthalmic examination
Neutropenia
• Consider growth factor support
• Dose reduction/hold
Diarrhea
• Educate patients
• Maintain hydration with electrolytes
• Antidiarrheal medications/best
supportive care
Management Strategies for Common AEs
EV SG
3. Treatments Used in Bladder Cancer
Full abbreviations, accreditation, and disclosure information available at PeerView.com/XJV40
1. Martins F et al. Nat Rev Clin Oncol. 2019;16:563. 2. Postow MA et al. N Engl J Med. 2018;378:158-168. 3. Schneider BJ et al. J Clin Oncol. 2021;39:4073-4126. 4. NCCN Clinical Practice Guidelines in Oncology. Management of Immunotherapy-Related Toxicities. Version 3.2023. https://www.nccn.org/
professionals/physician_gls/pdf/immunotherapy.pdf. 5. Hanna KS et al. Am J Health-Syst Pharm. 2022;79:629-635. 6. Trodelvy (sacituzumab govitecan-hziy) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. 7. Padcev (enfortumab vedotin)
Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761137s020lbl.pdf. 8. Knowles MA et al. Nat Rev Cancer. 2015;15:25-41. 9. Nimgaonkar N et al. JAMA Oncol. 2022;8:1070-1072. 10. LoriotY et al. N Engl J Med. 2019;381:338-348. 11. Siefker-Radtke AO et al.
Lancet Oncol. 2022;23:248-258.
FGFR Mutations Are Frequently Observed in Bladder Cancer8,9
Erdafinitib: Understanding Safety Considerations10-11
Patients ideally undergo testing upon
diagnosis
Options include specifically testing tumors
for FGFR3 alterations (eg, RT-PCR
companion assay) or more comprehensive
approaches (eg, NGS panels, liquid biopsy)
Both nurses and oncologists have
important roles in educating patients on
the importance of genomic testing
Eligibility for FGFR inhibition requires
testing for genomic alterations
• FGFR3 inhibitors are associated with
unique AEs
• Oral hygiene critical; mucositis and
other oral toxicities can be a concern
• Monitor for skin and nail toxicities,
referring to dermatology and podiatry
as needed
• Close monitoring and supportive care is
important
General Guidance on AEs
Associated With FGFR3 Inhibitors • Erdafitinib also inhibits FGFR signaling
in the proximal renal tubule, impairing
function of the sodium-dependent
phosphate co-transporter
• Dietary phosphate may require
restriction
– Consult a nutrition professional
(eg, registered dietitian, nutritionist)
for individualized dietary planning
– Consider adding a non–calcium-
containing phosphate binder (eg,
sevelamer carbonate)
• Recommended ophthalmologic
examinations
– Monthly for first 4 mo; every 3 mo
thereafter
– At any time for visual symptoms
• For any occurrence of central serous
retinopathy (CSR)/retinal pigment
epithelial detachment (RPED):
– Withhold erdafitinib; discontinue
permanently if symptoms do not
resolve in 4 wk
– Discontinue permanently for
grade 4 CSR/RPED
Bladder
lumen
Lamina
propria
Inner
muscle
Outer
muscle
Tis Ta
T1
T2a T2b T3
T4
Tumor invades
adjacent tissues
and organs
Tumor invades
perivesical tissue
Tumor invades
deep muscle
Tumor invades
superficial muscle
Tumor invades
subepithelial
connective tissue
Noninvasive
papillary
carcinoma
Carcinoma
in situ
Urothelium
Non-Muscle Invasive Muscle Invasive Metastatic
>60% ~30% ~30% ~20%
Hyperphosphatemia Ocular Toxicities
4. Expanding Role of Therapeutic Approaches in Bladder Cancer
Full abbreviations, accreditation, and disclosure information available at PeerView.com/XJV40
Neoadjuvant immunotherapy is administered before surgery and can reduce the
size of the primary tumor as well as eliminate residual cancer cells left after surgery
Rationale
• Lower disease burden and intact
immune system
• T-cell response generated against
in situ primary tumor with diverse
antigen load
• Fast endpoints to assess response
• Allows for translational research:
biologic and immunologic
correlative studies
Rationale
• Immunologic pathways are
disrupted by surgical stress
• No risk for delaying surgery with
adjuvant versus neoadjuvant
approach
• Prior chemotherapy or other
systemic/local therapies may help
augment immune responses
Adjuvant immunotherapy is administered after surgery and leads to an increase
in activated T cells that can eliminate residual cancer cells in the tumor bed
Comparison of Neoadjuvant and Adjuvant Treatment Approaches1
Immunotherapy
T cells
T-cell activation Resection surgery
Solid tumor Resection surgery Immunotherapy T-cell activation
and additional
immunotherapy
Tumor cells Artery Healthy cells Immunotherapy
5. Expanding Role of Therapeutic Approaches in Bladder Cancer
Full abbreviations, accreditation, and disclosure information available at PeerView.com/XJV40
Select Clinical Trials for NMIBC3
Pembrolizumab
FDA approved for the treatment of patients with BCG-unresponsive, high-risk NMIBC with carcinoma in situ with or without
papillary tumors who are ineligible for or have elected not to undergo cystectomy based on the KEYNOTE-057 trial2
Clinical Trials Testing TAR-200
• Phase 2 SunRISe-1: TAR-200 in BCG-unresponsive
• Phase 2 SunRISe-3: TAR-200 in BCG-naive
• Phase 1 TAR-210: FGFR alterations
Intravesical drug delivery system that enables a
sustained release of gemcitabine (TAR-200) or
erdafitinib (TAR-210) into the bladder, increasing the
dwell time of the local drug concentration
TAR-200/TAR-210
Clinical Trials Testing BCG + IO
• Phase 3 POTOMAC: BCG + durvalumab
• Phase 3 KEYNOTE-676: BCG + pembrolizumab
Key Eligibility Criteria
• High-risk NMIBC
• No prior BCG therapy
BCG
induction/maintenance +
CPI
BCG induction only +
CPI
BCG induction +
maintenance
R
6. Expanding Role of Therapeutic Approaches in Bladder Cancer
Full abbreviations, accreditation, and disclosure information available at PeerView.com/XJV40
1. Versluis JKM et al. Nat Med. 2020;26:475-484. 2. Balar AV et al. Lancet Oncol. 2021;22:919-930. 3. clinicaltrials.gov.
Approaches for MIBC3
Nivolumab
FDA approved for the adjuvant treatment of patients with MIBC
who are at high risk of recurrence after undergoing radical
resection based on the CheckMate -274 trial
Cisplatin-Eligible Trials
• Phase 3 ENERGIZE: gem/cis ±
nivolumab (fully accrued N = 861)
• Phase 3 NIAGARA: gem/cis ±
durvalumab (fully accrued N = 1,063)
• Phase 3 KEYNOTE-866:
gem/cis + pembrolizumab
(fully accrued N = 907)
• Phase 3 KEYNOTE-B15/EV-304:
pembrolizumab + EV
Cisplatin-Ineligable Trials
• Phase 3 KEYNOTE-905/EV-303:
pembrolizumab + EV
• Phase 3 VOLGA: durvalumab +
tremelimumab + EV
• Phase 2 SunRISe-4: TAR-200 +
cetrelimab
R
Cisplatin Ineligible
Neoadjuvant Phase
1:1:1
IO
IO +
novel agent
Radical cystectomy and
pelvic lymph node dissection
Adjuvant Phase
IO
IO +
novel agent
Observation
R
Cisplatin Eligible
Radical cystectomy and
pelvic lymph node dissection
Neoadjuvant Phase Adjuvant Phase
IO + chemo or
IO + novel agent
Placebo + chemo
IO or IO +
novel agent
Placebo
1:1
First-Line:
• Phase 2 BAYOU: durvalumab ± olaparib
in platinum-ineligible patients
• Phase 3 NILE: durvalumab + chemo ±
tremelimumab vs chemo
• Phase 3 CheckMate -901: nivolumab +
gem/cis vs gem/cis
• Phase 3 EV-302/KEYNOTE A-39:
enfortumab vedotin + pembrolizumab vs
chemo
Second-Line:
• Phase 2 DS8201-A-U105: T-DXd +
nivolumab
• Phase 2 DESTINY PanTumor02: T-DXd
in HER2+ mUC
• Phase 2 NORSE: erdafitinib + cetrelimab
vs erdafitinib
• Phase 3 THOR: erdafitinib vs chemo vs
pembrolizumab in patients with selected
FGFR mutations
• Phase 3 TROPiCS-04: sacituzumab
govitecan vs chemo
Approaches for Unresectable or mUC3
7. Patient Resources
for Healthcare Professionals1
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/XJV40
1. https://bcan.org.
The Bladder Cancer Advocacy Network (BCAN) is a national
advocacy organization that is committed to advancing bladder
cancer research and supporting those impacted by the disease.
BCAN provides free online and printed
educational resources designed to help
patients, caregivers, and the medical
community learn about bladder cancer
and treatment options.
• Printed materials
• Patient videos
• Webinars
• Podcasts
• Treatment matrix
• Clinical trials dashboard
• Bladder cancer support line:
833-ASK-4-BCA
Get Yours Today!